NCT00000923View on ClinicalTrials.gov

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

NACompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 2004

Conditions
HIV Infections
Interventions
DRUG

Indinavir sulfate

DRUG

Lamivudine

DRUG

Stavudine

DRUG

Zidovudine

DRUG

Didanosine

DRUG

Aldesleukin

Trial Locations (12)

10029

Mt. Sinai Med. Ctr. A0404 CRS, New York

35294

Alabama Therapeutics CRS, Birmingham

44106

Case CRS, Cleveland

52242

Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City

63112

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

70112

Tulane Univ. A1701 CRS, New Orleans

90502

Harbor-UCLA Med. Ctr. CRS, Torrance

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

98104

University of Washington AIDS CRS, Seattle

432101228

The Ohio State Univ. AIDS CRS, Columbus

900331079

USC CRS, Los Angeles

Unknown

Washington U CRS, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000923 - Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328 | Biotech Hunter | Biotech Hunter